PRKAA2

Across TCGA pan-cancer cohorts, PRKAA2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRKAA2 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PRKAA2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRKAA2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where PRKAA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.965	0.786	.005	45	view →
LUAD	DFS	Median	All	0.444	0.789	.002	10	view →
UCEC	OS	Quartile	All	1.000	0.867	.029	6	view →
HNSC	DFS	Tertile	III,IV	0.883	0.682	.014	4	view →
PDAC	OS	Median	All	0.740	0.955	.009	3	view →
GBM	OS	Median	All	0.896	0.814	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRKAA2–CCRCC (DFS)

Open the CCRCC breakdown →